PragmaTIL

The Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors (PragmaTIL) is a project that received funding from the European Union’s Horizon Europe research and innovation program under grant agreement No. 101104684 and started in 2023 with 12 partners across 6 countries. The PragmaTIL trial aims to optimize the treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment (TIL-ACT combined with ANV419) modality in academic hospitals. The global impact of this project will not only reach patients, clinical and translational researchers, and policymakers but may also help to achieve better acceptance of these therapies by society at large.